Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Addict. 2014 Sep-Oct;23(5):475-7. doi: 10.1111/j.1521-0391.2014.12133.x. Epub 2014 Mar 15.

A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole.

Author information

1
Department of Psychiatry and Biobehavioral Science, David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California.

Abstract

BACKGROUND:

Buprenorphine, used for treating opioid dependence, may have a withdrawal syndrome requiring treatment. Modulation of the dopamine system, which has been implicated in opioid withdrawal, may be a target for withdrawal for opioids such as buprenorphine.

CASE REPORT:

A case is reported of a buprenorphine withdrawal syndrome with predominant symptoms of restlessness that were resistant to clonidine and benzodiazepines. It was successfully treated with the dopamine agonist pramipexole.

SCIENTIFIC SIGNIFICANCE:

Dopamine receptor agonists may have a place in the treatment of restlessness associated with opioid withdrawal and may have value for the broader spectrum of opioid withdrawal symptoms.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center